Winning in the Margins: Commercial Strategy for New Entrants in the Adalimumab Autoinjector Market
Overview The adalimumab autoinjector market is becoming increasingly competitive, with multiple biosimilar manufacturers challenging established brands through aggressive pricing, product innovation, and evolving market access strategies. With 10 biosimilar competitors examined and discount levels reaching up to 85% versus Humira in the research, the commercial challenge extends beyond affordability. New entrants must differentiate through formulation, […]